- STRO -1.04%
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
Yahoo Finance · 2 weeks ago
Open | 3.7900 |
High | 3.8364 |
Low | 3.7450 |
Mkt Cap | 311.64M |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 3.8500 |
52 Wk. Low | 2.0100 |
52 Wk. High | 6.1300 |
Related stocks
Company
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 13.01M | 2.60% ▲ |
Net Income | -58.21M | - |
Diluted EPS | -0.95 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | -$0.79 | - |
Q1 2024 | -$0.92 | -$0.95 |
Q4 2023 | -$0.82 | $0.52 |
S&P 500^GSPC | 5,350.74-10.05 (-0.19%) |
Dow 30^DJI | 38,629.84-238.20 (-0.61%) |
Nasdaq^IXIC | 17,219.46+26.93 (+0.16%) |
858.97-0.70% | |
0.3488+50.93% | |
Apple Inc.AAPL | 204.43+5.85% |